FDA Approved: ERIBULIN MESYLATE — Original Application (Sandoz Inc)

View source ↗

Summary

The FDA approved Sandoz's original ANDA for ERIBULIN MESYLATE, authorizing the generic product's marketing in the United States.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Liposarcoma

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

ORIG AP for ERIBULIN MESYLATE (ERIBULIN MESYLATE)